Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-71P is a **processed RNA pseudogene** derived from the U6 small nuclear RNA gene but does not encode a functional transcript. U6 snRNA itself is a critical component of the spliceosome, coordinating the catalysis of pre-mRNA splicing, but the numerous pseudogenes, including RNU6-71P, are relics produced by retrotransposition and template-switching mechanisms involving LINE elements (such as L1)[3]. These pseudogenes do not participate in splicing, signal transduction, or other cell functions, nor are they active as drug targets or disease biomarkers. Instead, their existence marks the evolutionary history of small nuclear RNA retrotransposition in eukaryotic genomes[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 71, pseudogene (RNU6-71P).